Non-pregnant and non-lactating; women of child-bearing potential must have a negative urine or serum pregnancy test prior to registration; peri-menopausal women must be amenorrheic >=  months prior to registration to be considered not of childbearing potential
Patients must not be pregnant or nursing\r\n* Note: Peri-menopausal women must be amenorrheic for >  months to be considered not of childbearing potential
INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
INCLUSION CRITERIA FOR THIRD-LINE THERAPY: Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Pregnant or breast-feeding women; women of childbearing potential with either a positive or no pregnancy test at baseline; woman or men of childbearing potential not using a reliable and appropriate contraceptive method; (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment.
Women of childbearing potential must have a negative urine pregnancy test within  days prior to initiation of treatment; women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least  months)
Female participants who are pregnant or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to randomization; all women of childbearing potential must be willing to comply with an acceptable birth control regimen to prevent pregnancy while receiving treatment and for  months after treatment is discontinued as determined by the Investigator; post-menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential; (note: a woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives)
Women of childbearing potential must not be pregnant with a negative urine pregnancy test within  hours prior to registration and non-lactating; postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential; woman status post oophorectomy or hysterectomy are considered non-childbearing potential
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test at baseline; women/men of childbearing potential not using a reliable contraceptive method (oral contraceptive, other hormonal contraceptive, intrauterine device, diaphragm or condom); (postmenopausal women must have been amenorrheic for at least  months to be considered of non-childbearing potential); patients must agree to continue contraception for  days from the date of the last study drug administration
Females must have a negative serum pregnancy test  hours prior to the start of treatment or be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months)
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment; women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least  months); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Male or female patients of childbearing potential must be willing to use contraceptive precautions throughout the trial and  months following discontinuation of study treatment. Post-menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential.
Pregnant or lactating women; women of childbearing potential not using a reliable and appropriate contraceptive method; postmenopausal women must have been amenorrheic for at least  months to be considered of non-childbearing potential; patients will agree to continue the use of acceptable form of contraception for  days from the date of last drug administration
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and  months following discontinuation of study drug; post-menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential; women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib
Negative serum pregnancy test =<  days prior to registration for women of childbearing potential\r\n* NOTE: women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least  months)
Women of childbearing potential must have a negative urine pregnancy test within  days prior to initiation of treatment, women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post-menopausal (amenorrheic for at least  months)
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Women of childbearing potential must be non-pregnant (negative pregnancy test within  hours prior to registration; postmenopausal woman must have been amenorrheic and nonlactating for at least  months to be considered of non-childbearing potential; men and women of child bearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for  months after therapy is completed
Women of childbearing potential must have a negative urine pregnancy test within  days prior to initiation of treatment; women will be considered not of childbearing potential if they are surgically sterile (bilateral oophorectomy or hysterectomy) and/or post menopausal (amenorrheic for at least  months); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Women must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least  months) by the Investigator OR they must have a negative serum pregnancy test prior to randomization.
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment. Female subject considered not of childbearing potential must be documented as being surgically sterile or post-menopausal for at least  year. Women of childbearing potential and men must agree to use adequate contraception.
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment
Female patients of childbearing potential must have negative pregnancy test within  days before initiation of study drug dosing; postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential; male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to  months following discontinuation of study drug
Pregnant or lactating, or intending to become pregnant during the study: Women who are not postmenopausal (>= months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within  days prior to initiation of study drug
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test; women of child-bearing potential must have a negative pregnancy test prior to the first dose of bevacizumab; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and  months following the discontinuation of bevacizumab; post-menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Women of childbearing potential must be non-pregnant (negative pregnancy test within  hours prior to radiation simulation, postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential) and nonlactating, and men and women must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for  months after therapy completed
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and  months following discontinuation of study drug; post-menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential; women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib
Premenopausal and postmenopausal (amenorrheic for less than  months) women with either a positive or no pregnancy test (serum or urine) at baseline within  days study enrollment; postmenopausal women who are amenorrheic for more than  months do not require pregnancy test
Female patients of childbearing potential must have negative pregnancy test within  days before initiation of study drug dosing; postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential; surgical sterilization is considered non-childbearing potential; female patients of reproductive potential must agree to employ an effective method of birth control (hormonal or barrier) throughout the study and for up to  months following discontinuation of study drug
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative serum or urine pregnancy test within  hours before the start of the treatment
Pregnant or lactating women are not eligible; women of childbearing potential must have a negative serum or urine pregnancy test completed within  days of study treatment; women or men of childbearing potential not using a reliable and appropriate contraceptive method are not eligible; (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Pregnant or lactating women; female subjects of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of treatment; (postmenopausal women must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative serum pregnancy test within  days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Women of childbearing potential and men must agree to use adequate contraception prior to the study entry, for the duration of study participation and up to  months following completion of therapy. Women of childbearing potential must have a negative pregnancy test within  days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential.
Pregnant or lactating women are not eligible; women or men of childbearing potential not using a reliable and appropriate contraceptive method are not eligible (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential)
Women who are pregnant or breast-feeding; women of childbearing potential with a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless () surgically sterile or () using adequate measures of contraception (including two forms of contraception, one of which must be a barrier method) in the opinion of the investigator; perimenopausal women must be amenorrheic for at least  months to be considered of non-childbearing potential
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least  months) or if of childbearing potential, must have a negative urine pregnancy test within  hours or serum pregnancy test within  weeks of signing the informed consent document
Postmenopausal women must be amenorrheic for >=  months to be considered of non-childbearing potential
Patient must have non-pregnant status if a female of childbearing potential; women who have had a tubal ligation of at least  months prior to study entry or a hysterectomy will be considered NOT of childbearing potential; postmenopausal women must have been amenorrheic for at least  consecutive months to be considered NOT of childbearing potential
